EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Unipharma Co's Enterprise Value is NT$281.05 Mil.
Unipharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-38.55 Mil. Therefore, Unipharma Co's EV-to-FCF for today is -7.29.
The historical rank and industry rank for Unipharma Co's EV-to-FCF or its related term are showing as below:
ROCO:6621'
s EV-to-FCF Range Over the Past 10 Years
Min: -120.69 Med: -14.43 Max: 104.06
Current: -7.29
During the past 13 years, the highest EV-to-FCF of Unipharma Co was 104.06. The lowest was -120.69. And the median was -14.43.
ROCO:6621's EV-to-FCF is ranked worse than 100% of 561
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs ROCO:6621: -7.29
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Unipharma Co's PE Ratio (TTM) for today is calculated as:
Unipharma Co's share price for today is NT$11.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Unipharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Unipharma Co EV-to-FCF Related Terms
Unipharma Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Unipharma Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unipharma Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Unipharma Co's EV-to-FCF falls into.
Unipharma Co's current Enterprise Value is NT$281.05 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Unipharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-38.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unipharma Co (ROCO:6621) has a EV-to-FCF of -7.29 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Unipharma Co and its competitors. According to the industry distribution chart, Unipharma Co ranks #999999 out of 561 companies in the Drug Manufacturers industry.
Is Unipharma Co's EV-to-FCF too high?
Unipharma Co's current EV-to-FCF is -7.29. Based on the distribution chart, Unipharma Co ranks #999999 out of 561 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Unipharma Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unipharma Co ranks #999999 out of 561 companies for EV-to-FCF. This places Unipharma Co in the lower half of its industry. The industry median EV-to-FCF is 20.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Unipharma Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unipharma Co's current EV-to-FCF is -7.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.63, compared to a current price of NT$11.25 — trading 3.3% below its estimated fair value. The current EV-to-FCF is -7.29. Unipharma Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current EV-to-FCF is -7.29 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unipharma Co (ROCO:6621) Overvalued in 2026?
Based on GuruFocus' analysis, Unipharma Co stock appears to be undervalued.
The current stock price of NT$11.25 is trading 3.3% below its estimated GF Value™ of NT$11.63.
GuruFocus considers Unipharma Co to be Fairly Valued.
Key valuation signals for ROCO:6621:
EV-to-FCF: -7.29
GF Value™: NT$11.63 vs. price of NT$11.25 (3.3% below fair value)
No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
74GF Score
Get the complete analysis for ROCO:6621
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6621 has been successfully added to your 
